Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Biotechnology

Healthcare
$10.19 -1.58%

-$0.19 today

Market cap
$859.56M
Beta
0.84
P/E (TTM)
-24.1
EPS (TTM)
-$0.49
52W Low $3.55High $26.95

Volume 0.99M

Average 1.49M

CRVS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Corvus Pharmaceuticals, Inc.NASDAQ: CRVS

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income turns negative

Q1 FY2026 net income was -$13.69M, compared with $15.19M a year earlier. Trailing-twelve-month net income was -$44.17M. Over 3 fiscal years it compounded at -28.2% a year.

Context

  • Net income grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$56.23M (+267.9%) for the fiscal year ending Dec 2026, a step up from the -75.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$13.69M+11.1% QoQ
Last fiscal yearDec 2025
-$15.28M-75.5% YoY
LTMMar 2026
-$44.17M+6.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-190.1%+79.1%+269.3 pp
1 year-75.5%+267.9%+343.4 pp
3-year CAGR-28.2%+67.4%+95.6 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(15.28M) USD
Year-over-year change
+75.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How CRVS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +6.7% is the 6th highest of 8, against a peer median of +26.1%.
  • Over three fiscal years its annual growth of -28.2% compares with a peer median of -14.6%.
CRVS Competitors
Net Income for CRVS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$465.5M USD+369.3%—992.9%
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
NKTRNektar TherapeuticsLTM Jun 2026$157.13M USD+28.5%-23.6%287.8%
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$68.17M USD+23.5%+19.2%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$59.14M USD-242.2%-44.1%166.4%
IPHAInnate Pharma S.A.FY2025€49.18M EUR-0.6%-5.4%1764.5%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$44.17M USD+6.7%-28.2%—
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
ADAGAdagene Inc.LTM Jun 2024$31.85M USD—-39.6%3904.3%
Peer median (excluding CRVS) —+26.1%-14.6%340.5%

Competitors are the stored peer set for CRVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(43.24M)(41.31M)(27.03M)(62.29M)(15.28M)
Depreciation & Amortization460K367K151K85K105K
Deferred Income Tax00000
Stock-Based Compensation4.23M2.69M2.15M3M5.33M
Change in Working Capital(3.24M)1.41M(3.59M)(1.65M)3.58M
Accounts Receivables(507K)(81K)562K(49K)38K
Inventory00000
Accounts Payables(1.9M)411K(451K)1.06M(91K)
Other Working Capital(827K)1.08M(3.71M)(2.66M)3.63M
Other Non-Cash Items5.07M9.81M4.39M35.43M(26.53M)
Operating Cash Flow(36.72M)(27.02M)(23.94M)(25.42M)(32.8M)
Capital Expenditures(5K)(269K)(34K)0(174K)
Acquisitions (Net)(21.57K)22K05K0
Purchases of Investments(9.36M)(66.19M)(47.05M)(70.12M)(91.75M)
Sales of Investments30.92M43.16M62.62M42.63M84.13M
Other Investing Activities21.57K0000
Investing Cash Flow21.56M(23.28M)15.54M(27.48M)(7.8M)
Debt Repayment00000
Common Stock Issued60.94M07.84M16.41M36.43M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.22M012K32.62M0
Financing Cash Flow62.16M07.86M49.03M36.43M
Effect of Forex Changes00000
Net Change in Cash47M(50.3M)(539K)(3.88M)(4.16M)
Free Cash Flow(36.72M)(27.29M)(23.97M)(25.42M)(32.97M)

Corvus Pharmaceuticals, Inc.

NASDAQ:CRVS

Intrinsic Alpha fair value

Locked

Current Price

$10.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.